Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells

Tissue Antigens

Volumn 47, Issue 5, 1996, Pages 414-421

  Ostrand Rosenberg, S ^a   Baskar, S ^a   Patterson, N ^a   Clements, V K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

B7 1; B7 2; Costimulation; Metastasis; MHC class II; Tumor immunity

Indexed keywords

B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; GENETIC TRANSFECTION; HISTOCOMPATIBILITY GENE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALIA;

EID: 0030000166     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1996.tb02577.x     Document Type: Article

References (28)

1. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991: 49: 281-355.
2. Kern D, Klarnet J, Jensen, M, Greenberg P. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 1986: 136: 4303-10.
3. Schultz K, Klarnet J, Gieni R, Haylgass K, Greenber PH. The role of B cells for in vivo T cell responses to a friend virus-induced leukemia. Science 1990: 249: 921-3.
4. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990: 144: 4068-71.
5. Fearon D, Pardoll D, Itaya T, Golumbek P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990: 60: 397-403.
6. Swain S. T cell subsets and the recognition of MHC class. Immunol Rev 1983: 74: 129-42.
7. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern P. Natural history of HLA expression during tumour development. Immunol Today 1993: 14: 491-9.
8. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion vs. functional clonal inactivation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Annu Rev Immunol 1989: 7: 445-80.
9. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993: 11: 191-212.
10. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signaling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992: 360: 266-8.
11. Larsen CP, Ritchie SC, Pearson TC, Linsley PS, Lowry RP. Functional expression of the costimulatory molecule, B7/ BB1, on murine dendritic cell populations. J Exp Med 1992: 176: 1215-20.
12. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler L, Freeman G, Glimcher L. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A 1993: 90: 5687-90.
13. Ostrand-Rosenberg S, Roby C, Clements V. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol 1991: 147: 2419-22.
14. Landais D, Beck B, Buerstedde JM et al. The assignment of chain specificities for anti-la monoclonal antibodies using L cell transfectants. J Immunol 1986: 137: 3002-5.
15. O'Hare K, Benoist C, Breathnach R. Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. Proc Natl Acad Sci U S A 1981: 78: 1527-31.
16. Janeway C, Conrad PJ, Lerner EA, Babich J, Wettstein P, Murphy D. Monoclonal antibodies specific for Ia glycoproteins raised by immunization with activated T cells: possible role of T cell bound Ia antigens as targets of immunoregulatory T cells. J Immunol 1984: 132: 662-7.
17. Ozato K, Mayer N, Sachs D. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol 1980: 124: 533-40.
18. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995: 181: 619-29.
19. Chen C, Faherty D, Gault A et al. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J Immunol 1994: 152: 2105-14.
20. Kalebic T, Williams J, Talmadge JE et al. A novel method for selection of invasive tumor cells: derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity. Clin Exp Metastasis 1988: 4: 301-18.
21. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979: 63: 541-8.
22. Hart I. The selection and characterization of an invasive variant of the BL6 melanoma. Am J Pathol 1979: 97: 587-600.
23. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992: 71: 1093-102.
24. + T cells by B7-transfected melanoma cells. Science 1993: 259: 368-70.
25. St. Pierre YN, Nabavi N, Ghogawala Z, Glimcher LH, Watts T. A functional role for signal transduction via the cytoplasmic domains of MHC class II proteins. J Immunol 1989: 143: 808-12.
26. Nabavi N, Ghogawala A, Myer A et al. Antigen presentation abrogated in cells expressing truncated Ia molecules. J Immunol 1989: 142: 1444-7.
27. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom K. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994: 179: 523-43.
28. Chen PW, Ananthaswamy HN. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 1993: 151: 244-55.